Science news articles have been reporting on the pharmaceutical industry and the high cost of prescription drugs.
Discuss one of our topic ideas on pharmaceutical drugs. (Credit: Financial Tribune)
Some good research paper topics are to discuss new technological developments from the drug companies, and pro and con debates about the rise in drug costs.
Microchip in schizophrenia drug
A term paper topic could be to report on advances in pharmaceuticals. In a new development in drug delivery and monitoring called “digital pills,” Otsuka Pharmaceuticals has designed a microchip inside their Abilify pill that, when ingested, sends signals to a computer that alerts a doctor that the patient has indeed taken the pill. As patients often forget to take their medication, the chip inside the pill lets doctors know that their patients are complying with medication regimens. The aim is to improve patient outcome, monitor vital signs, reduce symptoms and obtain other patient information. Patients with mental illness, Alzheimer’s, bipolar disorder, depression and other conditions could benefit.
Digital chip for clinical trials
You could also write about the various uses for chips in pharmaceuticals. The digital chip could also be used for clinical trials and new drug development. Trevor Jones, a UK pharmaceuticals industry veteran and expert in clinical trials, said, “If you have an elderly person on a clinical trial and you ask her to take a pill for three months you cannot be sure that she has taken it every day. She might not admit it if she hasn’t because she doesn’t want to get in trouble with the doctor,” reported Andrew Ward in “US regulators accept ‘chip in a pill’ application,” posted September 10, 2015, in Financial Times.
Price gouging for pharmaceuticals
Not all developments in the pharmaceutical industry are advantageous. A current topic to write about is the skyrocketing price of drugs in America. A recent case that brought this issue to light was the outrageously brazen 5500% increase in the price of AIDS drug Daraprim. Turing Pharmaceuticals’ 32-year-old CEO Martin Shkreli bought the rights to the generic drug, then overnight raised the price of one pill from $13.50 to $750. Shkreli says the price increase is to recoup the investment in the drug and to benefit stakeholders.
Around the world, the news received harsh criticism and reinvigorated the debate of runaway drug costs. The situation has people like Dr. Peter Bach, director of the Center for Health Policy at Memorial Sloan Kettering Cancer Center in New York, lamenting that Shkreli raised the drug price just because he could. Bach said, “I think it reflects a widespread appreciation that pricing for drugs is entirely irrational in this country, and the pharmaceutical industry has total control over prices and there’s no rationality to the system,” reported Carolyn Y. Johnson in “Drug’s Pricing Proves a Defining Moment in Modern Health Care,” posted in Washington Post September 27, 2015.
Drug price restriction debate
A great topic for a term paper is to discuss the pros and cons of high drug prices. Most countries around the world restrict the price drug companies can charge, while the United States does not. On the pro side, Darius Lakdawalla, professor of pharmaceutical development at the University of Southern California, said that drug price controls would not save much money, and that the money lost to drug companies from high prices would stifle innovation and development. “Our research shows that when prices fall, innovation falls even more. Patients would see their lives cut short by delayed or absent drugs,” he said in “Drug Price Controls End Up Costing Patients Their Health” in New York Times September 23, 2015.
On the con side, Jared Bernstein, senior fellow at the Center on Budget and Policy Priorities and economic adviser to Vice President Joe Biden, explained that the pharmaceutical industry is a distorted market—a free market does not allow the price of goods to rise 5500% overnight. As for price restriction, Bernstein said in “Drug Price Controls Are Vital in a Market That’s Not Free” in New York Times September 23, 2015: “The producers argue that this will stifle their incentive to innovate. But the evidence is increasingly clear that we cannot count on the private sector to make necessary medicines affordable. In fact, given the incentive structure, neither can we count on private drug companies to develop the drugs we most need versus the ones that will be most profitable.”
For more information, check out Questia’s library on the Pharmaceutical Industry.
Do you think there should be a price cap on pharmaceutical drugs?
1. Angell M. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York: Random House; 2004.
2. Angell M. Your Dangerous Drugstore, June 8. NY Rev Books. 2006. pp. p38–40.
3. Baty P. Data Row Sparks Research Debate. THES. 2005. pp. p39–40. November 25.
4. Berger VW. Improving the Information Content of Categorical Clinical Trial Endpoints. Controlled Clinical Trials. 2002;23:p502–514.[PubMed]
5. Berger VW, Rezvani A, Makarewicz VA. Direct Effect on Validity of Response Run-In Selection in Clinical Trials. Controlled Clinical Trails. 2003;24:p156–166.[PubMed]
6. Chen A, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials. JAMA. 2007;291:p2457–2465.[PubMed]
7. Dresser R. Pharmaceutical Company Gifts: From Voluntary Standards to Legal Demands. Hastings Cent Rep. 2006;36:p8–9.[PubMed]
8. Elliott C. Pharma Goes to the Laundry: Public Relations and the Business of Medical Education. Hastings Cent Rep. 2004;34:p19.[PubMed]
9. Fava G. Long-Term Treatment with Antidepressant Drugs: The Spectacular Achievements of Propaganda. Psychother Psychosom. 2002;71:p127–132.[PubMed]
10. Fava G. Conflicts of Interest in Psychopharmacology: Can Dr. Jekyll Still Control Mr. Hyde? Psychother Psychosom. 2004;73:p1–4.[PubMed]
11. Fava G. A Different Medicine is Possible. Psychother Psychosom. 2006;75:p1–3.[PubMed]
12. Fugh-Berman A. The Corporate Coauthor. J Gen Intl Med. 2005;20:p547.
13. Glassman PA, Hunter-Hayes J, Nakamura T. Pharmaceutical Advertising Revenue and Physicians Organizations: How Much is too Much? Western J of Med. 1999;171:p234–238.[PMC free article][PubMed]
14. Golden GA, Parochka JN, Parochka JN, Overstreet KM. Medical Education and Communication Companies: An Updated In-Depth Profile. J Contin Educ Health Prof. 2002;22:p55–62.[PubMed]
15. Gottlieb S. Medical societies accused of being beholden to the drugs industry. BMJ. 2006;319:p1321.[PMC free article][PubMed]
16. Healy D. Let Them Eat Prozac. New York: New York University Press; 2004.
17. Herman E, Chomski N. Manufacturing Consent: The Political Economy of the Mass Media. New York: Pantheon Books; 1988.
18. Horton R. The Dawn of McScience. NY Rev Books. 2004. pp. p7–9. March 11.
19. Kesselheim A, Avorn J. The Role of Litigation in Defining Drug Risks. JAMA. 2007;297:p308–11.[PubMed]
20. Krimsky S. Publication Bias, Data Ownership and the Funding Effect in Science: Threats to the Integrity of Biomedical Research. In: Wagner W, Steinzor R, editors. Rescuing Science from Politics: Regulation and Distortion of Scientific Research. Cambridge: Cambridge University Press; 2006. pp. p61–85.
21. Lexchin J, Light D. Commercial Influence and the Content of Medical Journals. BMJ. 2006;332:p1444–1447.[PMC free article][PubMed]
22. McHenry L. On the Origin of Great Ideas: Science in the Age of Big Pharma. Hastings Cent Rep. 2005;35:p17–19.[PubMed]
23. Popper K. The Open Society and its Enemies. London: Routledge; 1945. 2 vols.
24. Popper K. The Poverty of Historicism. New York: Harper Torchbooks; 1961. pp. p154–55.
25. Popper K. Conjectures and Refutations: The Growth of Scientific Knowledge. London: Routledge; 1963.
26. Schafer A. Biomedical Conflicts of Interest: a Defense of the Sequestration Thesis-Learning From the Cases of Nancy Olivieri and David Healy. J Med Ethics. 2004;30:p8–24.[PMC free article][PubMed]
27. Singh A, Singh S. Medicine as a Corporate Enterprise, Patient Welfare Centered Profession or Patient Welfare Centered Professional Enterprise? Mens Sana Monographs. 2005;3:p19–51.[PMC free article][PubMed]
28. Singh A, Singh S. The Image of Pharma. Mens Sana Monographs. 2007a;5:p37–44.[PMC free article][PubMed]
29. Singh A, Singh S. Clinical Practice Guidelines and Industry. Mens Sana Monographs. 2007b;5:p44–55.[PMC free article][PubMed]
30. Singh A, Singh S. Academia, Journal Publishing and the Bio-Medical Industry. Mens Sana Monographs. 2007c;5:p11–14.[PMC free article][PubMed]
31. Smith R. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. Plos Med. 2005;2:p e138.[PMC free article][PubMed]
32. Smith R. Lapses at the New England Journal of Medicine. J Royal Society Med. 2006;99:p1–3.[PMC free article][PubMed]